25 related articles for article (PubMed ID: 19188672)
1. Cardiac Metabolic Deregulation Induced by the Tyrosine Kinase Receptor Inhibitor Sunitinib is rescued by Endothelin Receptor Antagonism.
Sourdon J; Lager F; Viel T; Balvay D; Moorhouse R; Bennana E; Renault G; Tharaux PL; Dhaun N; Tavitian B
Theranostics; 2017; 7(11):2757-2774. PubMed ID: 28824714
[TBL] [Abstract][Full Text] [Related]
2. Quantitative and qualitative changes in platelet traits of sunitinib-treated patients with renal cell carcinoma in relation to circulating sunitinib levels: a proof-of-concept study.
Tullemans BME; Brouns SLN; Swieringa F; Sabrkhany S; van den Berkmortel FWPJ; Peters NAJB; de Bruijn P; Koolen SLW; Heemskerk JWM; Aarts MJB; Kuijpers MJE
BMC Cancer; 2022 Jun; 22(1):653. PubMed ID: 35698081
[TBL] [Abstract][Full Text] [Related]
3. Haemoglobin level increase as an efficacy biomarker during axitinib treatment for metastatic renal cell carcinoma: a retrospective study.
Johnson AC; Matias M; Boyle H; Escudier B; Molinier A; Laguerre B; Helissey C; Brachet PE; Dugué AE; Mourey L; Coquan E; Joly F
BMC Cancer; 2017 May; 17(1):355. PubMed ID: 28532444
[TBL] [Abstract][Full Text] [Related]
4. Effects of vascular endothelial growth factor signaling inhibition on human erythropoiesis.
Bhatta SS; Wroblewski KE; Agarwal KL; Sit L; Cohen EE; Seiwert TY; Karrison T; Bakris GL; Ratain MJ; Vokes EE; Maitland ML
Oncologist; 2013; 18(8):965-70. PubMed ID: 23900000
[TBL] [Abstract][Full Text] [Related]
5. Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients.
Fujiwara Y; Kiyota N; Chayahara N; Suzuki A; Umeyama Y; Mukohara T; Minami H
Invest New Drugs; 2012 Jun; 30(3):1055-64. PubMed ID: 21301929
[TBL] [Abstract][Full Text] [Related]
6. Targeted therapies in renal cell cancer: recent developments in imaging.
van der Veldt AA; Meijerink MR; van den Eertwegh AJ; Boven E
Target Oncol; 2010 Jun; 5(2):95-112. PubMed ID: 20625845
[TBL] [Abstract][Full Text] [Related]
7. Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?
Gotink KJ; Verheul HM
Angiogenesis; 2010 Mar; 13(1):1-14. PubMed ID: 20012482
[TBL] [Abstract][Full Text] [Related]
8. The current status and evolving role of sunitinib in non-small cell lung cancer.
Socinski MA
J Thorac Oncol; 2008 Jun; 3(6 Suppl 2):S119-23. PubMed ID: 18520293
[TBL] [Abstract][Full Text] [Related]
9. [Cutaneous side effects of sorafenib and sunitinib].
Autier J; Mateus C; Wechsler J; Spatz A; Robert C
Ann Dermatol Venereol; 2008 Feb; 135(2):148-53; quiz 147, 154. PubMed ID: 18342102
[No Abstract] [Full Text] [Related]
10. Sunitinib-induced hemoglobin changes are related to the dosing schedule.
van der Veldt AA; Boven E; Vroling L; Broxterman HJ; van den Eertwegh AJ; Haanen JG
J Clin Oncol; 2009 Mar; 27(8):1339-40; author reply 1340-2. PubMed ID: 19188672
[No Abstract] [Full Text] [Related]
11. Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome.
Kapiteijn E; Brand A; Kroep J; Gelderblom H
Ann Oncol; 2007 Oct; 18(10):1745-7. PubMed ID: 17890216
[No Abstract] [Full Text] [Related]
12. Summaries for patients. Underactive thyroid function after treatment with sunitinib for gastrointestinal cancer.
Ann Intern Med; 2006 Nov; 145(9):I44. PubMed ID: 17088575
[No Abstract] [Full Text] [Related]
13. Sporadic CNS hemangioblastomatosis, response to sunitinib and secondary polycythemia.
Reyes-Botero G; Gállego Pérez-Larraya J; Sanson M
J Neurooncol; 2012 Apr; 107(2):439-40. PubMed ID: 22076450
[No Abstract] [Full Text] [Related]
14. Treatment of hemodialyzed patient with sunitinib.
Reckova M; Kakalejcik M; Beniak J
Ann Oncol; 2009 Feb; 20(2):392-3. PubMed ID: 19136449
[No Abstract] [Full Text] [Related]
15. Bevacizumab + sunitinib: microangiopathic haemolytic anaemia. A serious drug interaction between 2 cancer drugs.
Prescrire Int; 2009 Aug; 18(102):165. PubMed ID: 19746526
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
